Re-defining synthetic lethality by phenotypic profiling for precision oncology

Area of Science:

• Genomics
• Cancer Biology
• Drug Discovery

Background:

• High-throughput screening enables systematic phenotypic discovery.
• Synthetic lethality (SL) is a key paradigm for anticancer drug and target discovery.
• Identifying therapeutically relevant SL interactions presents significant challenges.

Purpose of the Study:

• To explore how high-throughput screening can identify selective synthetic lethality interactions.
• To introduce an extended concept of SL for anticancer applications.
• To discuss computational quantification and exploitation of tumor heterogeneity for precision oncology.

Main Methods:

• Utilizing high-throughput functional and genomic screening techniques.
• Applying synthetic lethality as a model for drug and target discovery.
• Investigating computational quantification of synergistic interactions and cancer selectivity.

Main Results:

• Screening technologies offer new possibilities for identifying therapeutically relevant SL interactions.
• An extended concept of SL, involving simultaneous perturbation, is proposed for anticancer applications.
• Tumoral heterogeneity can be leveraged for phenotype-specific SL interactions in precision oncology.

Conclusions:

• High-throughput screening methods provide exciting opportunities for discovering novel SL interactions.
• The extended SL concept and computational approaches enhance potential for anticancer drug development.
• Exploiting tumoral heterogeneity via screening advances precision oncology and subclonal SL interaction identification.